Cargando…

P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH.

Detalles Bibliográficos
Autores principales:	Kulasekararaj, Austin, Brodsky, Robert, Griffin, Morag, Röth, Alexander, Piatek, Caroline, Ogawa, Masayo, Yu, Ji, Patel, Yogesh, Fernandez, Fernando Ataulfo Gonzalez, Nishimura, Jun-Ichi, Peffault de Latour, Régis, Szer, Jeff, Wook Lee, Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430716/ http://dx.doi.org/10.1097/01.HS9.0000969992.63273.36

Ejemplares similares

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up
por: Yenerel, Mustafa N., et al.
Publicado: (2022)

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
por: Brodsky, Robert A., et al.
Publicado: (2020)

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021)

PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: de Latour, Régis Peffault, et al.
Publicado: (2023)

P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS
por: Kulasekararaj, A., et al.
Publicado: (2022)

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies
por: Kulasekararaj, Austin G., et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
por: Peffault de Latour, Régis, et al.
Publicado: (2020)

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
por: Peffault de Latour, Régis, et al.
Publicado: (2023)

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO
por: Wook Lee, Jong, et al.
Publicado: (2023)

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020)

S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL
por: Risitano, Antonio Maria, et al.
Publicado: (2023)

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
por: Shikdar, Sufana, et al.
Publicado: (2021)

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
por: Höchsmann, Britta, et al.
Publicado: (2023)

PB2056: PREVALENCE OF CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS IN STABLE C5 INHIBITOR-TREATED PATIENTS WITH PNH AND ITS ASSOCIATION WITH DISEASE CONTROL, QUALITY OF LIFE AND TREATMENT SATISFACTION
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

PB2065: SEVERE HEMOLYSIS OF PNH PATIENTS ASSOCIATED WITH OMICRON INFECTION IN CHINA
por: Yang, Hui, et al.
Publicado: (2023)

A complementary new drug for PNH
por: Brodsky, Robert A.
Publicado: (2020)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan
por: Fattizzo, Bruno, et al.
Publicado: (2022)

P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
por: Szer, Jeff, et al.
Publicado: (2023)

Intravascular Hemolysis in Aluminum Phosphide Poisoning
por: Malakar, Sayan, et al.
Publicado: (2019)

Characteristics of Taiwanese patients of PNH in the international PNH registry
por: Chou, Wen-Chien, et al.
Publicado: (2016)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
por: Sharma, Ruby, et al.
Publicado: (2015)

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)
por: Weisshaar, Kimmo, et al.
Publicado: (2020)

Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis
por: Merle, Nicolas S., et al.
Publicado: (2018)

Naphthalene Toxicity: Methemoglobinemia and Acute Intravascular Hemolysis
por: Volney, Giselle, et al.
Publicado: (2018)

Clostridium perfringens Septicemia with Massive Intravascular Hemolysis
por: Fujikawa, Hirohisa, et al.
Publicado: (2019)

Massive intravascular hemolysis associated with Clostridium perfringens bacteremia
por: Poletti, Giovanni, et al.
Publicado: (2021)

P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB
por: Yenerel, M. N., et al.
Publicado: (2022)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

A case of severe intravascular hemolysis in a young girl
por: Shastry, Shamee, et al.
Publicado: (2011)

Babesia microti Causing Intravascular Hemolysis in Immunocompetent Child, China
por: Yao, Jiafeng, et al.
Publicado: (2023)

S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Scheinberg, Phillip, et al.
Publicado: (2023)

Massive acute intravascular hemolysis after platelet transfusion: An unrecognized entity
por: Jain, Vishakha V., et al.
Publicado: (2011)

Acute intravascular hemolysis due to naphthalene toxicity: a case report
por: Uthuman, A. A. A., et al.
Publicado: (2019)

Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Role of Toll‐like receptor 4 in intravascular hemolysis‐mediated injury
por: Vázquez‐Carballo, Cristina, et al.
Publicado: (2022)

Intravascular Hemolysis, Methemogolbinemia and Acute Renal Failure in a Young Female
por: Gupta, Ashish, et al.
Publicado: (2023)

Ravulizumab: Lack of efficacy: case report
Publicado: (2022)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ou10d8opaub9n5vucumb9g6kle